Advanced Search

Technical Analysis for GSK - GlaxoSmithKline PLC

Grade Last Price % Change Price Change
grade D 39.9 -1.16% -0.47
GSK closed down 0.88 percent on Thursday, July 9, 2020, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
6 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical GSK trend table...
Date Alert Name Type % Chg
20 DMA Resistance Bearish -1.16%
Stochastic Reached Oversold Weakness -1.16%
Outside Day Range Expansion -1.16%
Oversold Stochastic Weakness -1.16%
Inside Day Range Contraction -2.04%
Gapped Down Weakness -1.19%
Fell Below 20 DMA Bearish -2.71%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.71%
Outside Day Range Expansion -2.71%
Crossed Above 20 DMA Bullish -3.20%
Older EOD signals for GSK ...
View Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also produces paediatric and adult vaccines to prevent a range of infectious diseases, including hepatitis A and B; diphtheria, tetanus, and whooping cough; measles, mumps, and rubella; polio; typhoid; influenza; and bacterial meningitis. In addition, it provides consumer health products in oral care, nutritional, total wellness, and skin health areas. The company's total wellness products include Panadol for the treatment of paracetamol-based treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; ENO Tums, a rapid relief antacid; and oral care products comprise Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to improve comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. Its nutrition products include Lucozade for energy and hydration; and Horlicks and Maxinutrition for nutrition; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Energy Medicine Health Cancer Pharmaceutical Drugs Infectious Diseases Medication Pharmaceutical Products Rare Diseases Influenza Asthma HIV Nutrition Products Antibiotic Infections Wellness Products Depression Oral Care Products Eczema Fever Smoking Cessation Glaxosmithkline Nicotine Consumer Health Products Hepatitis A Joint Pain Measles Mumps Preventive Healthcare Rubella Tetanus

Is GSK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Jul 10 Karyopharm up 5% on uncertainty with advisory committee nod for Glaxo drug
Jul 10 FDA advisory committee nod not a given for Glaxo antibody-drug conjugate for treatment-resistant multiple myeloma
Jul 10 FDA says to review side effect of GSK's multiple myeloma drug
Jul 10 Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal
Jul 10 Britain to set out its position on EU vaccine scheme later on Friday
Jul 8 Moderna completes enrollment in mid-stage study of COVID-19 vaccine
Jul 8 Glaxo Signs Another Deal to Develop a Coronavirus Vaccine
Jul 8 PRESS DIGEST-British Business - July 8
Jul 7 GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact
Jul 7 Novavax Gets Funding; Brazil Leader Tests Positive: Virus Update
See more GSK news...

Indicators

Indicator Value
52 Week High 48.25
52 Week Low 31.43
Average Volume 3,051,186
200-Day Moving Average 42.67
50-Day Moving Average 41.38
20-Day Moving Average 40.90
10-Day Moving Average 40.78
Average True Range 0.74
ADX 14.23
+DI 17.49
-DI 29.36
Chandelier Exit (Long, 3 ATRs ) 40.55
Chandelier Exit (Short, 3 ATRs ) 42.04
Upper Bollinger Band 41.72
Lower Bollinger Band 40.09
Percent B (%b) 0.17
BandWidth 3.99
MACD Line -0.19
MACD Signal Line -0.14
MACD Histogram -0.0567
Fundamentals Value
Market Cap 98.67 Billion
Num Shares 2.44 Billion
EPS 1.03
Price-to-Earnings (P/E) Ratio 39.19
Price-to-Sales 2.27
Price-to-Book 83.56
PEG Ratio 1.10
Dividend 1.99
Dividend Yield 4.93%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.69
Resistance 3 (R3) 41.75 41.38 41.47
Resistance 2 (R2) 41.38 41.04 41.35 41.40
Resistance 1 (R1) 40.87 40.83 40.69 40.81 41.32
Pivot Point 40.50 40.50 40.40 40.47 40.50
Support 1 (S1) 39.99 40.16 39.81 39.93 39.42
Support 2 (S2) 39.62 39.95 39.59 39.34
Support 3 (S3) 39.11 39.62 39.27
Support 4 (S4) 39.05